ArticleEuropean thyroid journal2026
Prevalence and outcome of metastases to the thyroid gland: a nationwide database study.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetastases to the thyroid are seen relatively often in autopsy studies. In clinical studies, they are described as a rare occurrence. This study aimed to provide a more extensive representation of the origin, timing, and survival of patients diagnosed with thyroid metastases in the Netherlands.
methodsWe performed a retrospective database study using two Dutch nationwide resources. In the Dutch Nationwide Pathology Databank (PALGA) database, we identified 575 patients between 1989 and 2014 with proven thyroid metastases. These patient records were linked with data from the Netherlands Cancer Registry (NCR) to assess whether the presence of these metastases had any impact on patients' survival. Complete survival data were available for 463 patients.
resultsThe most frequently diagnosed primary tumors were lung (29.4%), kidney (16.5%), and breast carcinoma (10.1%). However, thyroid metastases can originate from any primary tumor. The median time to diagnosis of thyroid metastasis was 17.2 months after the primary diagnosis. In 36 patients, the latency period was over 10 years. In 77% of patients, thyroid metastasis was part of pathologically proven widespread disease. Survival after diagnosis of thyroid metastasis was poor, with a median survival of 12.3 months.
conclusionClinically relevant metastases to the thyroid are relatively rare and occur in a large variety of tumor types. Most of them occur in the context of advanced metastatic disease, and therefore, prognosis and indication for surgical treatment depend on the extent of the primary tumor, general health of the patient, and presence of local symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.